U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
07 sept. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
New Drug Application for Oxbryta dispersible tablets also accepted for priority review Approximately 17,000 children ages 4 to 11 years have sickle cell disease in the United States SOUTH SAN...
GBT Announces Participation in Upcoming Investor Conferences
02 sept. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in virtual fireside chats at the...
GBT Announces New Employment Inducement Grants
12 août 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2021, the compensation committee of GBT’s board...
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
04 août 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush...
GBT Reports Second Quarter 2021 Financial Results
03 août 2021 16h05 HE
|
Global Blood Therapeutics, Inc.
Achieved Oxbryta® (voxelotor) net revenues of $47.6 million, an increase of 51% year-over-year Continued progress toward potential Oxbryta pediatric label expansion in U.S. and marketing...
GBT to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
27 juil. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2021 financial results on...
GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease (SCD)
22 juil. 2021 07h00 HE
|
Global Blood Therapeutics, Inc.
Submits Supplemental New Drug Application to the U.S. FDA for Oxbryta® (voxelotor) in Children with SCD Ages 4 to 11 Initiates Phase 3 Clinical Trials of Inclacumab and Enrolls First SCD Patient in...
GBT Announces New Employment Inducement Grants
09 juil. 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2021, the compensation committee of GBT’s board of...
GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease
15 juin 2021 08h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) has awarded approximately $450,000 to U.S. community-based organizations and...
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
14 juin 2021 07h00 HE
|
Global Blood Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. and LONDON, June 14, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT), a biopharmaceutical company dedicated to the discovery, development and...